1. Home
  2. ABVC vs ATNM Comparison

ABVC vs ATNM Comparison

Compare ABVC & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ABVC BioPharma Inc.

ABVC

ABVC BioPharma Inc.

N/A

Current Price

$1.07

Market Cap

34.6M

Sector

Health Care

ML Signal

N/A

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

N/A

Current Price

$1.25

Market Cap

31.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ABVC
ATNM
Founded
2015
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.6M
31.7M
IPO Year
2009
2013

Fundamental Metrics

Financial Performance
Metric
ABVC
ATNM
Price
$1.07
$1.25
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.50
AVG Volume (30 Days)
94.7K
161.7K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
7.14
14.17
EPS
N/A
0.71
Revenue
$509,589.00
$90,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$1.97
Revenue Growth
N/A
11.11
52 Week Low
$0.71
$0.74
52 Week High
$3.39
$1.74

Technical Indicators

Market Signals
Indicator
ABVC
ATNM
Relative Strength Index (RSI) 56.47 66.29
Support Level $0.96 $0.96
Resistance Level $1.14 $1.38
Average True Range (ATR) 0.08 0.08
MACD 0.03 0.03
Stochastic Oscillator 89.06 73.33

Price Performance

Historical Comparison
ABVC
ATNM

About ABVC ABVC BioPharma Inc.

ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

Share on Social Networks: